Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,822.00p on 19-12-2025 at 19:40:06
Change 9.50p 0.52%
Buy 1,817.00p
Sell 1,816.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 25,000.00 at 1,800.25076p
Day's Volume: 20,121,835
Last Close: 1,822.00p
Open: 1,805.00p
ISIN: GB00BN7SWP63
Day's Range 1,798.50p - 1,822.00p
52wk Range: 1,242.50p - 1,853.50p
Market Capitalisation: £73.51b
VWAP: 1,815.96432p
Shares in Issue: 4.03b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 25,000 1,800.25076p Negotiated Trade
 16:51:00 - 19-Dec-25
Buy* 1,158 1,822.00p SI Trade
Negotiated Trade
 16:49:58 - 19-Dec-25
Sell* 36,139 1,814.861p SI Trade
Suspected SELL Trade
 16:47:17 - 19-Dec-25
Unknown* 530,057 1,822.00p SI Trade
 16:44:04 - 19-Dec-25
Buy* 8,425 1,822.00p Ordinary
 16:42:14 - 19-Dec-25
Buy* 19,315 1,822.00p Ordinary
 16:42:11 - 19-Dec-25
Buy* 8,261 1,822.00p Ordinary
 16:42:11 - 19-Dec-25
Buy* 50,400 1,822.00p Suspected BUY Trade
 16:42:11 - 19-Dec-25
Buy* 1,491 1,822.00p Ordinary
 16:42:11 - 19-Dec-25
Buy* 39,018 1,822.00p Automatic Execution
 16:37:49 - 19-Dec-25
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
19th Dec 2025 (Fri) 1,805.00 1,822.00 1,798.50 1,822.00 20,121,835
18th Dec 2025 (Thu) 1,817.50 1,820.00 1,797.50 1,812.50 7,352,624
17th Dec 2025 (Wed) 1,826.00 1,850.50 1,823.50 1,833.50 10,914,252
16th Dec 2025 (Tue) 1,844.50 1,850.00 1,816.00 1,819.50 7,636,767
15th Dec 2025 (Mon) 1,819.00 1,838.50 1,810.00 1,833.50 10,789,160
12th Dec 2025 (Fri) 1,816.50 1,837.50 1,815.00 1,824.50 11,917,084
11th Dec 2025 (Thu) 1,805.00 1,821.00 1,792.50 1,821.00 8,075,205
10th Dec 2025 (Wed) 1,780.00 1,807.50 1,769.50 1,803.50 6,940,061
9th Dec 2025 (Tue) 1,821.00 1,822.50 1,780.00 1,783.00 8,159,545
8th Dec 2025 (Mon) 1,812.50 1,822.00 1,802.50 1,820.50 5,964,130
5th Dec 2025 (Fri) 1,826.50 1,833.00 1,796.00 1,805.00 4,275,273
4th Dec 2025 (Thu) 1,827.50 1,853.50 1,818.50 1,826.00 9,013,434
3rd Dec 2025 (Wed) 1,835.00 1,848.50 1,830.00 1,833.00 9,068,561
2nd Dec 2025 (Tue) 1,786.50 1,828.00 1,781.50 1,819.00 8,473,958
1st Dec 2025 (Mon) 1,790.50 1,823.00 1,783.00 1,800.00 12,290,851
28th Nov 2025 (Fri) 1,809.50 1,809.50 1,785.50 1,791.00 4,299,102
27th Nov 2025 (Thu) 1,805.00 1,812.00 1,795.50 1,802.00 8,413,515
26th Nov 2025 (Wed) 1,798.50 1,820.00 1,794.50 1,814.00 10,807,305
25th Nov 2025 (Tue) 1,789.50 1,809.00 1,778.00 1,795.00 9,012,395
24th Nov 2025 (Mon) 1,793.50 1,794.00 1,774.50 1,794.00 22,545,525
21st Nov 2025 (Fri) 1,756.50 1,788.00 1,753.00 1,788.00 8,671,411
20th Nov 2025 (Thu) 1,778.00 1,783.00 1,755.00 1,760.50 8,550,402
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
19th Dec 2025 7:00 am RNS Transaction in Own Shares
19th Dec 2025 7:00 am RNS Transaction in Own Shares
18th Dec 2025 7:00 am RNS Transaction in Own Shares
17th Dec 2025 7:00 am RNS Exdensur (depemokimab ulla) approved by US FDA
17th Dec 2025 7:00 am RNS Transaction in Own Shares
16th Dec 2025 7:00 am RNS Exdensur (depemokimab) UK MHRA approval
16th Dec 2025 7:00 am RNS Transaction in Own Shares
15th Dec 2025 7:00 am RNS Transaction in Own Shares
12th Dec 2025 1:50 pm RNS Nucala receives positive CHMP opinion for COPD
12th Dec 2025 1:41 pm RNS Depemokimab receives positive CHMP opinion
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

IN BRIEF: GSK announces drug price deal with US government

19th Dec 2025 22:11

GSK PLC - London-based pharmaceuticals firm - Announces agreement with the US government to lower the cost of prescription medicines for American patients, including GSK's portfolio for respiratory conditions such as asthma and COPD. Says it will lower the price of certain medicines in Medicaid and "launch new products with a more balanced pricing approach", and will make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform with savings of up to 66%. Furthermore, it intends to further support the US supply chain for critical medicines by securing a reserve of albuterol, the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD, for the US. Read More

LONDON MARKET CLOSE: FTSE 100 and sterling rise after BoE rate cut

18th Dec 2025 17:16

(Alliance News) - Stock prices in London closed in the green on Thursday, following the Bank of England's decision to cut rates and a hold from the European Central Bank. Read More

GSK secures US FDA approval for "innovative" severe asthma treatment

17th Dec 2025 09:50

(Alliance News) - GSK PLC on Wednesday said its Exdensur treatment, depemokimab, for severe asthma has been approved by the US Food & Drug Administration. Read More

GSK receives UK marketing approval for asthma treatment Exdensur

15th Dec 2025 20:48

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. Read More

GSK hails positive opinion by EU's CHMP on depemokimab and Nucala

12th Dec 2025 14:23

(Alliance News) - GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value9,897.42
Change59.65

Login to your account

Forgot Password?

Not Registered